Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.
Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Sohn SK, et al. Among authors: joo yd. Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463107 Clinical Trial.
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients.
Seong SJ, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR. Seong SJ, et al. Among authors: joo yd. Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31. Ann Oncol. 2013. PMID: 23117072 Free article.
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party. Koh Y, et al. Among authors: joo yd. Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24. Ann Hematol. 2010. PMID: 20179930 Clinical Trial.
Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: fludarabine versus cyclophosphamide-ATG.
Kim H, Lee KH, Kim I, Sohn SK, Jung CW, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Kim MK, Bae SH, Shin HJ, Won JH, Lee WS, Oh S, Kim HJ, Park JH; Korean Society of Blood and Marrow Transplantation. Kim H, et al. Among authors: joo yd. Leuk Res. 2014 Jul;38(7):730-6. doi: 10.1016/j.leukres.2014.01.002. Epub 2014 Jan 10. Leuk Res. 2014. PMID: 24840870
Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis.
Song GY, Jung SH, Lee JJ, Kim JS, Min CK, Kim K, Choi Y, Eom HS, Joo YD, Kim SH, Kwak JY, Kang HJ, Lee JH, Lee HS, Mun YC, Moon JH, Sohn SK, Park SK, Park Y, Shin HJ, Yoon SS. Song GY, et al. Among authors: joo yd. Leuk Lymphoma. 2020 Nov;61(11):2714-2721. doi: 10.1080/10428194.2020.1783448. Epub 2020 Jun 25. Leuk Lymphoma. 2020. PMID: 32580672
A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia.
Lee JH, Joo YD, Kim H, Bae SH, Kim MK, Zang DY, Lee JL, Lee GW, Lee JH, Park JH, Kim DY, Lee WS, Ryoo HM, Hyun MS, Kim HJ, Min YJ, Jang YE, Lee KH; Cooperative Study Group A for Hematology. Lee JH, et al. Among authors: joo yd. Blood. 2011 Oct 6;118(14):3832-41. doi: 10.1182/blood-2011-06-361410. Epub 2011 Aug 9. Blood. 2011. PMID: 21828126 Free article. Clinical Trial.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Kim DY, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology. Kim DY, et al. Among authors: joo yd. Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11. Blood. 2015. PMID: 26065651 Free article. Clinical Trial.
Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment.
Shin HJ, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party; Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM. Shin HJ, et al. Among authors: joo yd. Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25. Jpn J Clin Oncol. 2010. PMID: 20185460
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study.
Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, Chung JS, Kim H, Lee WS, Joo YD, Yang DH, Kook H, Kang HJ, Ahn HS, Yoon SS, Sohn SK, Min YH, Min WS, Park HS, Won JH. Kim SJ, et al. Among authors: joo yd. Haematologica. 2010 Nov;95(11):1935-42. doi: 10.3324/haematol.2010.026104. Epub 2010 Jul 27. Haematologica. 2010. PMID: 20663943 Free PMC article. Clinical Trial.
87 results